A study about how well emicizumab prevents bleeding in haemophilia A patients and its overall impact on their health outcomes
Phase 4
- Conditions
- Health Condition 1: D66- Hereditary factor VIII deficiency
- Registration Number
- CTRI/2024/07/069770
- Lead Sponsor
- Rnt medical College
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
New Confirmed case of hemophilia A
Patients with a documented baseline bleeding frequency, allowing for a comparison of bleeding episodes before and after emicizumab treatment
Patients who give informed consent
Exclusion Criteria
Presence of coagulation disorders other than hemophilia A, which may confound the study results
Significant comorbidities or medical conditions that may independently affect the outcomes of interest. Like liver diseases
Patients without proper informed consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method